OPERATION
BLANKETROL II, Model 222S
OPERATION AND TECHNICAL MANUAL
Page 33 of 110
Warning
A physician’s order is required for setting blanket temperature and use of equipment. At least every
20 minutes, or as directed by the physician, check patient’s temperature and skin integrity of areas
in contact with blanket; also, check the BLANKETROL I
I’s water temperature. Pediatric patients,
temperature-sensitive patients with vascular disease, surgical patients, diabetics and patients with
Raynaud’s Disease are at greater risk for developing tissue injuries, and this should be considered
when selecting the temperature, duration of therapy and frequency of skin checks.
Notify the
physician promptly of any change in patient status in order to avoid serious injury or death.
The method of temperature control provided by all hyper-hypothermia units presents the danger of
heating or cooling body tissues, particularly the skin, to a point where they are injured, i.e. burns or
frostbite, respectively. The clinician is responsible for determining the appropriateness of the
temperature limits in dependency to time. Exceeding 40°C water temperature for extended periods
can cause tissue damage and burns. Clinical judgment should be used to determine the safe
maximum contact periods based on patient age, clinical condition, and current medications.
Depending on the extent and severity of a burn, very serious and even fatal complications
may arise.
Do not use the BLANKETROL II System distal to arterial cross clamping.
Thermal injury may
result.
Thermal injury may occur
if heating/cooling therapy is applied to ischemic limbs.
The warming of transdermal medications (patches) can increase drug delivery,
resulting in
possible injury to the patient.
Prevent excessive and/or prolonged tissue pressure and shearing forces, especially over bony
prominences.
Failure to do so may result in tissue injury.
Do not place additional heat sources between the patient and blanket.
Tissue damage may result.
Means to maintain contact between the patient and the blanket during therapy may be required and
should not block the fluid pathways of the blanket or connecting hose.
Failure to do so may result
in inadequate treatment.
Prep solutions have been reported to injure the skin when allowed to remain between patients and a
water-circulating heating blanket during prolonged procedures. Use of materials of good thermal
conductivity, such as water, gel and similar substances, with the BLANKETROL II not switched ON
may decrease the temperature of the patient.
The area between the patient and the blanket
should be kept dry to avoid injury to patient.
Proper sanitation procedures must be practiced and hygienic safety must be maintained, to prevent
contamination.
Contamination can affect patient’s health, i.e. skin irritation/rash may result.
Use only YSI 400 Series, or equivalent, probes on CSZ equipment (refer to list of accessories in
Figure (6-9)).
Failure to do this will cause incorrect temperature readings and may result in
inadequate/inappropriate treatment.
Due to static electricity, a 400 Series Probe may not be connected to the BLANKETROL II unit
without first discharging one’s body to the frame of the BLANKETROL II unit or another grounded
object.
Failure to do so may result in damage from electrostatic discharge (ESD).
All staff that
may touch the 400 Series Probe must be familiar with this warning and basic static electricity or
electrostatic discharge (ESD) training.
Basic static electricity or ESD training should include an introduction to the physics of electrostatic
charge, the voltage levels that can occur in normal practice and the damage that can be done to
electronic components if equipment is touched by an operator who is electrostatically charged.
Further, an explanation should be given of methods to prevent build-up of electrostatic charge, and
how and why to discharge one’s body to the BLANKETROL II unit or another grounded object.
Failure to do so may result in damage from electrostatic discharge (ESD).
Do not use the BLANKETROL II system in the presence of flammable anesthetics.
Risk of
explosion can result.
Summary of Contents for CSZ Blanketrol II 222S
Page 112: ......
